Core Insights - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines aimed at correcting abnormal gene expression to treat serious diseases, with an initial emphasis on oncology [1][4] - The company utilizes its proprietary Gene Traffic Control® platform to identify and validate potential drug targets within the chromatin regulatory system, which has the potential to transform treatment options for a wide range of diseases [1][4] Conference Participation - Foghorn management will participate in the Jefferies London Healthcare Conference on November 19, 2024, with a fireside chat led by CEO Adrian Gottschalk [2] - The company will also engage in one-on-one meetings during the 7th Annual Evercore HealthCONx Conference on December 3, 2024, and the Citi Global Healthcare Conference on December 4, 2024 [3][2] Company Overview - Foghorn Therapeutics is dedicated to discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system, with multiple product candidates currently in development for oncology [4]

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.19%. A quarter ago, it was expected that this company would post a loss of $0.60 per share when it actually produced a loss of $0.45, delivering a surprise of 25%.Over the last four quarters, the company has s ...

Foghorn Therapeutics Inc. (FHTX) closed the last trading session at $8.28, gaining 35.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15 indicates an 81.2% upside potential. The average comprises five short-term price targets ranging from a low of $6 to a high of $20, with a standard deviation of $5.83. While the lowest estimate indicates a decline of 27.5% from the current pri ...

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 2024 Wells Fargo Healthcare Conference and presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline ...

Foghorn Therapeutics Inc. (FHTX) closed the last trading session at $6.20, gaining 2.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.75 indicates a 121.8% upside potential. The mean estimate comprises four short-term price targets with a standard deviation of $5.91. While the lowest estimate of $6 indicates a 3.2% decline from the current price level, the most optimistic ana ...

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.70 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this company would post a loss of $0.55 per share when it actually produced a loss of $0.59, delivering a surprise of -7.27%. Over the last four quarters, the company has ...

Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and public policy leader Raj Panjabi, M.D., MPH, will join Flagship as Senior Partner. Dr. Panjabi will lead Flagship's Preemptive Health and Medicine Initiative (PH&M), which is pioneering a new field to protect, maintain ...

The Abiologics platform leverages cutting-edge generative AI and high throughput chemical protein synthesis to create Synteins™, a new class of programmable medicines that aims to redefine what therapeutics can achieve for patients CAMBRIDGE, Mass., July 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Abiologics, a company reimagining biologics with the creation of a new class of supranatural and programmable medicines, called Synteins™. Synteins are computat ...

Record Year with Key Partnerships, Global Expansion and Expanded Top Talent "Over the past six years, Flagship has also pioneered AI-enabled platforms that transform drug discovery, speed up the drug development process and gain new insights into human health and sustainability," Afeyan added. "By leveraging the power and potential of generative AI, we're embracing a future in which companies are created and expanded in ways we have not previously experienced, with the prospect for unprecedented impact." Pa ...

Core Insights - Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines that correct abnormal gene expression to treat serious diseases, with an initial emphasis on oncology [1][3] - The company utilizes its proprietary Gene Traffic Control® platform to identify and validate drug targets within the chromatin regulatory system, aiming to transform the treatment landscape for various diseases [3] Conference Participation - Foghorn Therapeutics will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 3:30 p.m. ET, with CEO Adrian Gottschalk as the presenter [2] - The company will also participate in one-on-one meetings during the Jefferies conference [2] - Additionally, Foghorn will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 3:20 p.m. ET, again featuring CEO Adrian Gottschalk [2] - One-on-one meetings will also be held during the Goldman Sachs conference [2] Company Overview - Foghorn Therapeutics is engaged in discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system [3] - The company is developing multiple product candidates specifically in the oncology sector [3] - More information about the company can be found on its website and social media platforms [3]